PALM SPRINGS, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Dynamic Alert Limited (OTC Bulletin Board: DYMC) is pleased to announce that it has now identified its target markets for its pharmaceutical product line-up. The modalities will include a lozenge with some capacity for enhancing rapid onset through oromucosal absorption, topical applications, such as lotions and salves, and various products for internal use. Some products will have specific uses, while others may treat a range of problems. In keeping with both the historic medical uses of cannabis and the new scientific understanding of how cannabinoids work, Dynamic's cannabinoid pharmaceuticals will be targeting a wide-variety of serious needs such as:
1. Neuro-muscular disorders, such as MS. 2. Neuropathic pain, related to spinal cord injuries, as well as conditions such as AIDS/HIV and the side-effects of its medications, etc. for which opiates are not very effective. 3. Chronic pain, to reduce or eliminate patients' dependence on opiates. 4. Respiratory inflammation, related to both infections such as influenza and to autoimmune diseases such as asthma. 5. Cancer, including pain management, control of nausea resulting from chemotherapy as well as loss of appetite related to the disease itself. 6. Also control of cancer in conditions such as Pheochromocytoma. 7. Digestive illnesses, such as gastroesophageal reflux disease (GERDS), Crohn's Disease and irritable bowel syndrome. 8. Dermatological infections, such as MRSA (flesh eating disease). 9. Sleep disorders.
President & CEO, Richard Cowan, states, "We are certainly pleased at the
speed in which our business model is rolling out. The potential market size
for some of these products is obviously very large. When multiplied by the
various categories and compounded by multiple country rollouts, we are
|SOURCE Dynamic Alert Limited|
Copyright©2008 PR Newswire.
All rights reserved